MA45890A1 - Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes - Google Patents

Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Info

Publication number
MA45890A1
MA45890A1 MA45890A MA45890A MA45890A1 MA 45890 A1 MA45890 A1 MA 45890A1 MA 45890 A MA45890 A MA 45890A MA 45890 A MA45890 A MA 45890A MA 45890 A1 MA45890 A1 MA 45890A1
Authority
MA
Morocco
Prior art keywords
patient
pharmaceutical composition
opioids
composition intended
composition
Prior art date
Application number
MA45890A
Other languages
English (en)
Other versions
MA45890B2 (fr
Inventor
Catherine Stehman-Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45890A1 publication Critical patent/MA45890A1/fr
Publication of MA45890B2 publication Critical patent/MA45890B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique destinée à prévenir une dépendance aux opioïdes chez un patient. La composition peut être utilisée chez un patient souffrant de lombalgie (lbp) modérée à sévère. La composition est avantageuse chez un patient ayant reçu un diagnostic de lombalgie, et comprend une quantité thérapeutiquement efficace d'un anticorps qui se lie plus particulièrement au facteur de croissance nerveuse (ngf) ou d'un fragment de liaison à l'antigène de ce dernier; et elle est utilisée en l'absence d'un opioïde servant à atténuer la douleur, et prévient la dépendance aux opioïdes chez un patient.
MA45890A 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes MA45890B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Publications (2)

Publication Number Publication Date
MA45890A1 true MA45890A1 (fr) 2020-02-28
MA45890B2 MA45890B2 (fr) 2022-10-31

Family

ID=60766150

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45890A MA45890B2 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Country Status (16)

Country Link
US (2) US10736961B2 (fr)
EP (1) EP3548082B1 (fr)
JP (1) JP7071975B2 (fr)
KR (1) KR20190090820A (fr)
CN (1) CN110072549A (fr)
AU (1) AU2017366870A1 (fr)
BR (1) BR112019010331A2 (fr)
CA (1) CA3045116A1 (fr)
CL (1) CL2019001385A1 (fr)
CO (1) CO2019005247A2 (fr)
EA (1) EA201991283A9 (fr)
IL (1) IL266640B (fr)
MA (2) MA45890B2 (fr)
MX (1) MX2019006013A (fr)
PH (1) PH12019501087A1 (fr)
WO (1) WO2018102294A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11472870B2 (en) 2018-08-10 2022-10-18 Regeneron Pharmaceuticals, Inc. Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
WO2023092052A1 (fr) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Méthodes et compositions pour réduire la douleur centralisée
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ZA200504866B (en) 2002-12-24 2006-11-29 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2009023540A1 (fr) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
EA034617B1 (ru) 2010-10-06 2020-02-27 Ридженерон Фармасьютикалз, Инк. Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)

Also Published As

Publication number Publication date
MX2019006013A (es) 2019-10-14
JP7071975B2 (ja) 2022-05-19
CL2019001385A1 (es) 2019-07-26
MA46951A (fr) 2019-10-09
US10736961B2 (en) 2020-08-11
EA201991283A9 (ru) 2019-11-27
KR20190090820A (ko) 2019-08-02
AU2017366870A1 (en) 2019-06-06
CA3045116A1 (fr) 2018-06-07
IL266640A (en) 2019-07-31
US11491222B2 (en) 2022-11-08
CO2019005247A2 (es) 2019-05-31
WO2018102294A1 (fr) 2018-06-07
BR112019010331A2 (pt) 2019-10-22
US20210060159A1 (en) 2021-03-04
JP2019535716A (ja) 2019-12-12
EA201991283A1 (ru) 2019-09-30
MA45890B2 (fr) 2022-10-31
PH12019501087A1 (en) 2019-08-19
US20180147280A1 (en) 2018-05-31
EP3548082A1 (fr) 2019-10-09
IL266640B (en) 2022-09-01
EP3548082B1 (fr) 2024-05-15
CN110072549A (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA45890A1 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
MA43283B1 (fr) Composition pour le traitement du cancer
MA35035B1 (fr) Anticorps polypeptidiques qui antagonisent les cd40
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
EA202190335A1 (ru) Композиции антител против fcrn и способы их применения
MA34135B1 (fr) Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique
Tan et al. Genus Calliophis of Asiatic coral snakes: A deficiency of venom cross-reactivity and neutralization against seven regional elapid antivenoms
AR111767A1 (es) Proteínas de unión al antígeno anti-jagged1
Takanashi et al. Extracellular cyclophilin A possesses chemotaxic activity in cattle
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
Lowry The placenta is simply a neuroendocrine parasite
MA41668A1 (fr) Composition multi-pertidique